Polyclonal Immunoglobulin Recovery in Patients with Newly Diagnosed Myeloma Receiving Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation with Either Carfilzomib, Lenalidomide and Dexamethasone or Lenalidomide Alone: Subanalysis of the Randomized Phase III ATLAS Trial

Investigators performed a longitudinal analysis of polyclonal immunoglobulin concentrations and unique B cell sequences in patients enrolled in the Phase III ATLAS trial that randomized 180 subjects to either carfilzomib, lenalidomide, dexamethasone, or lenalidomide maintenance.